Clinical Trial Detail

NCT ID NCT04529044
Title 177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors OHSU Knight Cancer Institute
Indications

breast carcinoma

Therapies

lutetium Lu 177 dotatate

Age Groups: senior adult

No variant requirements are available.